NCT03608020
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Radiation therapy, Other

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: Brain
Additional Notes: Patients must have 10+ contrast-enhancing lesions never previously treated with SRS and/or surgical resection- see trial for details
Exclusions: Patients with leptomeningeal disease or prior whole brain radiation therapy
https://ClinicalTrials.gov/show/NCT03608020